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ABSTRACT. Context: Hypokalemic periodic paraly-
sis (HypoPP) is a rare disorder consisting of sudden 
episodes of muscle weakness with areflexia involv-
ing all four limbs, which spontaneously resolve 
within several hours or days. Primary HypoPP is 
genetically determined, while secondary acquired 
HypoPP has been described in association with thy-
reotoxycosis, hyperaldosteronism, kidney diseas-
es, diuretics and liquorice abuse, gastrointestinal 
potassium loss, or cysplatinum therapy. Objective: 
To report a case of HypoPP associated with GH de-
ficiency. Patient: A 33 yr-old man with hypopituitar-
ism and diabetes insipidus secondary to pituitary 
stalk-localized sarcoidosis, and documented Hy-
poPP episodes. Clinical Presentation: Neurologic 
exam outside HypoPP episodes was normal. Nee-
dle electromyography was normal without myoto-
nia or other spontaneous electric activity. Muscle 
biopsy documented a vacuolar myopathy with tu-
bular aggregates. However, genetic analysis ruled 
out common mutations of the voltage-gated calci-
um channel observed in primary HypoPP. Common 
causes of secondary HypoPP were also ruled out. 
The patient was diagnosed with severe GH defi-
ciency with modest fasting hyperinsulinemia and 
insulin resistance and started on GH replacement 
therapy, an α-glucosidase inhibitor (acarbose) and 
a diet low in simple carbohydrates. Conclusions: 
GH replacement therapy, acarbose and a diet low 
in simple carbohydrates resulted in the complete 
long-term (>2 yr) remission of HypoPP episodes. 
This is consistent with the hypothesis that the hy-
perinsulinemia associated to GH deficiency may 
trigger HypoPP episodes by increasing Na+/K+ AT-
Pase activity and K+ transport into the intracellular 
compartment with subsequent hypokalemia. 
(J. Endocrinol. Invest. 30: 341-345, 2007)
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INtroDUCtIoN
Hypokalemic periodic paralysis (HypoPP) is a rare 
disorder characterized by sudden episodes of mus-
cle weakness with areflexia involving all four limbs, 
usually occurring on awakening, after exercise or 
carbohydrate-rich meals (1, 2). Prodromic symptoms 
include xerostomy, thirst, and tachycardia. Spon-
taneous recovery may take several hours or days. 
Involvement of respiratory muscles and arrhythmias 
secondary to electrolyte imbalance are rare (1, 2).
Primary HypoPP is an autosomal dominant disease, 
caused by mutations in the voltage-gated calcium 
channel gene CACNA1S (3) or, less frequently, by 
mutations in the voltage-gated sodium channel gene 
SCNA4A (4-6). Muscle biopsy (2) and response to 
acetazolamide (6) are used to differentiate between 
these two forms of primary HypoPP. Secondary or 
acquired forms of HypoPP are mostly observed dur-
ing adulthood and may be associated with thyreo-
toxycosis (7), hyperaldosteronism (8), kidney diseases 
(9), diuretics and liquorice abuse (10), gastrointestinal 
potassium loss (11), and cysplatinum therapy (12). 
Primary forms are treated using the carbonic anhydrase 
inhibitors acetazolamide and dichlorophennamide 
(13, 14). In case of life-threatening hypokalemia, intra-
venous potassium supplementation is mandatory. In 
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secondary or acquired forms of HypoPP, the treatment 
of the underlying disease will prevent further HypoPP 
episodes. In both primitive and secondary forms of Hy-
poPP patients are advised to avoid precipitant factors. 
We report the case of HypoPP occurring in an adult 
male with hypopituitarism secondary to neurosar-
coidosis, who had regression of HypoPP episodes with 
combined GH replacement and acarbose therapy.
Case report
A 33-yr-old man was referred to the Endocrinology 
Unit at the San Raffaele Scientific Institute in Milan, 
with a 2-yr history of progressive weight gain, fa-
tigue, myalgias and recurrent post-prandial episodes 
of sudden limb weakness evolving to complete pa-
ralysis. Several of those episodes required admission 
to an emergency department, where severe hypoka-
lemia was repeatedly documented (lowest value re-
ported during paralysis: 1.8 mmol/l). Paralysis would 
resolve spontaneously after many h of rest or after iv 
potassium administration. 
Family history was negative for HypoPP or muscle-
weakness episodes. Repeated neurologic exams out-
side the paralytic episodes were normal. Two years 
before admission the patient was diagnosed with 
hypopituitarism and diabetes insipidus secondary to 
stalk-localized sarcoidosis. Pathology on a stereotac-
tic biopsy showed chronic giant cell-, non-caseating-
granulomatous hypophysitis. The patient received 
Table 1 - Antropometric parameters, biochemical and hormonal profile of the patient.
Parameters Before therapy After 6 months of therapy
BMI (kg/m2) 32.4 31.2
IGF-I (ng/ml, nv 115-307)
TSH (mU/l, nv 0.27-4.20)
fT4 (ng/dl, nv 0.93-1.70)
fT3 (ng/l, nv 1.8-4.6)
Glycated hemoglobin (%, nv 3.5-6.0)
S-fasting glucose (mg/dl, nv 65-110)
S-fasting insulin (μU/ml, nv 5-25)
HOMA-S % 
HOMA-β %
S-creatinine (mg/dl, nv 0.5-1.25)
Microalbuminuria (mg/dl, nv<15)
U-pH (nv 5-6.5)
S-potassium (mmol/l, nv 3.5-5.0)
S-sodium (mmol/l, nv 135-148)
S-total calcium (mmol/l, nv 2.10-2.60)
S-ionized calcium (mmol/l, nv 1.18-1.30)
S-phosphate (mmol/l, nv 0.8-1.5)
S-chloride (mmol/l, nv 96-108)
U-potassium (mmol/24 h, nv 30-90)
U-sodium (mmol/24 h, nv 40-220)
U-calcium (mmol/24 h, nv 2-10)
U-phosphate (mmol/24 h, nv 11-32) 
U-cytrate (mg/24 h, nv 349-956)
S-aldosterone clin (pg/ml, nv 30-150)
S-aldosterone ort (pg/ml, nv 70-350)
P-renin activity clin (ng/Al/ml/h, nv 0.2-2.8)
P-renin activity ort (ng/Al/ml/h, nv 1.5-5.7)
P-parathyroid hormone (pg/ml, nv 10-65)
S-osteocalcin (ng/ml, nv 1.1-7.2)
25OH-D3 vitamin D (ng/ml, nv 10-68)
107
0.01
1.06
3.5
4.9
80
15
53.7
188.8
0.7
11
6.2
3.6
138
2.29
1.22
1.29
103
49
135
1.9
56.07
440
35
73
1.47
2.81
58
5.8
15
158
0.01
1.18
3.7
4.7
84
12
65.9
147.5
0.8
Not evaluated
Not evaluated
4.12
140
2.36
1.25
1.37
102
52
128
8.0
36.50
Not evaluated
43
81
1.38
2.5
30
7.7
21
Hemogasanalisis:
pH (nv 7.35-7.45)
pCO2  (mm Hg, nv 35-45)
pO2  (mm Hg, nv 80-110)
Bicarbonate (mmol/l, nv 22-26)
CO2 (mmol/l, nv 23-27)
Base excess (mol/l, nv 2.0-3.0)
O2 saturation hemoglobin (%, nv 95-98)
7.387
38.4
80
22.6
20
–2.1
96.7
BMI: body mass index; HOMA-S: homeostasis model assessment for insulin sensitivity; HOMA-β: homeostasis model assessment for β-cells function; 
nv: normal values; fT3: free T3; fT4: free T4; P: plasma; U: urine; S: serum.
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immunosuppressive therapy with oral prednisone (1 
mg/kg/day) that was progressively tapered and re-
placed with cortisone acetate and oral methotrexate 
(the latter stopped after 1 yr). At the time of admission 
the patient was on cortisone acetate (25 mg/day), tes-
tosterone enantate (250 mg/15 days), l-thyroxine (75 
μg/day) and intranasal desmopressin (0.125 mg b.i.d.) 
replacement therapy. Anthropometric, biochemical 
and hormonal parameters are shown in Table 1. Re-
placement therapy was adequate. Free T3, free T4 
levels, plasma renin activity, and serum aldosterone 
levels in clino and orthostatism were within the normal 
range. Kidney function was normal with unremarkable 
urinalysis. Sarcoidosis-related renal tubular acidosis 
(15) was ruled out based on a normal urinary pH and 
urinary citrate excretion (Table 1). The patient had no 
diarrhea, and reported no use of diuretics or licorice, 
nor history of cysplatinum exposure. Furthermore, se-
rum electrolyte levels and urinary electrolyte excretion 
were normal. Needle electromyography (EMG) was 
normal with no myotonia or other spontaneous elec-
tric activity recorded. Nerve conduction velocity was 
also normal. Muscle biopsy showed a vacuolar myop-
athy with tubular aggregates (Fig. 1A, B, C, D), as ob-
served in skeletal muscle channelopathies. However, 
genetic analysis ruled out the common mutations on 
the voltage-gated calcium channel gene CACNA1S 
Arg528Hys and CACNA1S Arg1239Hys and of the 
voltage-gated sodium channel gene on domain D2 
Arg672Hys/Gly, Arg669Hys, and Arg672Ser.
A GHRH (1 μg/kg iv) + arginine (0.5 μg/kg iv) stimu-
lation test documented severe GH deficiency (GH 
peak 1.7 μg/l), confirmed by the finding of low circu-
lating IGF-I levels (107 ng/ml, nv 115-307). Magnetic 
resonance imaging of the hypothalamic-pituitary re-
gion showed slight thickening of the pituitary stalk 
with enhancement after gadolinium administration, 
compatible with the previous diagnosis of stalk-lo-
calized sarcoidosis. We estimated insulin sensitivity 
and β-cell function using the homeostasis model 
assessment (HOMA-S and HOMA-β, respectively) 
(16). Hyperinsulinemia and insulin resis-tance were 
documented (Table 1), as expected in hypopituitary 
adults with GH deficiency (17). 
GH replacement therapy was started at a dose of 
0.3 mg/day sc. The patient was also prescribed an 
α-glucosidase inhibitor (acarbose 200 mg t.i.d.) and 
a diet including 50% of complex carbohydrates, 
both aimed at reducing insulin peaks in response to 
meals. Since the start of treatment in February 2004, 
the patient reported no further HypoPP episodes or 
complaints of fatigue and muscle pain. 
DIsCUssIoN
We reported a case of HypoPP secondary to GH 
deficiency in an adult male with hypopituitarism due 
to pituitary stalk-localized neurosarcoidosis. To our 
knowledge, this is the first report of HypoPP associ-
ated to adult GH deficiency. Conditions commonly 
Fig. 1 - Muscle biopsy (magnification 400x). 
Hematoxylin and eosin (H&E) staining 
shows peripheral basophilic aggregates 
(Panel A, arrow) and an optically empty 
vacuol (Panel B, arrowhead). Basophilic ag-
gregates show intense reactivity on nicoti-
namide adenine dinucleotide-tetrazolium 
reductase (NADH-TR) staining (Panel C), 
but are mostly negative on succinic dehy-
drogenase (SDH) staining (Panel D).
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associated with HypoPP, such as hyperthyroidism, 
primary hyperaldosteronism, diuretics abuse, 
gastrointestinal potassium loss, and sarcoidosis-
related renal tubular acidosis were ruled out. Glu-
cocorticoids abuse as a cause of hypokalemia was 
excluded for the following reasons: 1) at the time of 
the hypokalemic episodes, the patient showed no 
clinical features of glucocorticoid excess; 2) a facti-
tious increase of steroid dosage was likely to persist 
also after the start of GH replacement therapy, when 
the hypokalemic episodes promptly disappeared; 3) 
in case of glucocorticoid excess, the expected effect 
would be chronic hypokalemia, rather than acute 
hypokalemic episodes after meals or at awakening. 
Neuromuscular symptoms during paralytic attacks 
were undistinguishable from those of a primary skel-
etal muscle calcium or sodium channel hypokalemic 
periodic paralysis. However, a genetic form of Hy-
poPP was unlikely since the patient had no family his-
tory of HypoPP and common mutations for CACN1A 
and SCN4A were excluded.
The mechanism triggering a HypoPP episode in 
a patient with GH deficiency remains a matter of 
speculation. A direct effect of GH on the ion chan-
nels involved in the pathogenesis of HypoPP can-
not be excluded but, to our knowledge, it has never 
been demonstrated. We hypothesized that the hy-
perinsulinemia accompanying GH deficiency docu-
mented in our patient may increase Na+-K+ ATPase 
activity (18). This, in turn, would increase potassium 
transport into the intracellular compartment with 
subsequent hypokalemia. The prompt regression 
of HypoPP episodes observed in our patient im-
mediately after starting treatment with GH and an 
α-glucosidase inhibitor is consistent with this hy-
pothesis. The hypothesis of a decreased effective-
ness of cortisone therapy because of GH-depen- 
dent inhibition of 11β-hydroxysteroid-dehydroge-
nase type 1 (19) seemed unlikely, since there was no 
need for adjustment of cortisone dose after the start 
of GH replacement therapy. The need for an under-
lying predisposing genetic or epigenetic condition, 
resulting in an ionic transmembrane electrolyte im-
balance (7, 20), has been shown for HypoPP associ-
ated with thyreotoxicosis and may partly explain why 
HypoPP does not occur in all patients with GH defi-
ciency. The need for a predisposing genetic factor 
is also suggested by a previous study showing that 
insulin-induced hypoglycemia is not associated with 
an increased risk of hypokalemia among hypopitui-
tary adults with GH deficiency compared to individu-
als with normal anterior pituitary function (21).
In conclusion, GH deficiency may be another 
cause of secondary (acquired) HypoPP. GH defi-
ciency should be considered in patients with un-
explained, episodic muscle weakness with a history 
of hypothalamic/pituitary disorders. Replacement 
therapy with recombinant GH, and dietetic/phar-
macological approaches to reduce hyperinsuline-
mia may obtain complete long-term remission of 
HypoPP episodes. 
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